Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target
Climb Bio, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $11.80
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS